… & Voulgarelis, M. (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-…
& Lazzarino, M. (2003) Treatment of polycythemia vera and essential thrombocythemia: the …

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including
polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (…

The leucocyte common antigen, protein tyrosine phosphatase receptor type C (PTPRC), also
known as CD45, is a transmembrane glycoprotein, expressed on almost all haematopoietic …

Background The V617F mutation, which causes the substitution of phenylalanine for valine
at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with …

We present a review of critical concepts and produce recommendations on the management
of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, …

… Patients also were randomized to receive ATRA 45 mg/m 2 per day for 60 days. Policies
with regard to blood product support, antibiotic and antifungal prophylaxis, and treatment of …

Background Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia,
and myelofibrosis, are chronic hematologic cancers with varied progression rates. …

… of 45 mg/m 2 until … /m 2 on days 2, 4, 6, and 8 of course 1, and then at 5 mg/m 2 on days 1–4
of course 2; mitoxantrone at 10 mg/m 2 on days 1–4 of course 3, and idarubicin at 12 mg/m 2 …

… (Investigation of EPOR and VHL gene mutations can be analysed by sending an EDTA
sample by post to Dr M Percy, Department of Haematology, C Floor, Belfast City Hospital, Lisburn …

To assess factors influencing the success of whole-genome sequencing for mainstream
clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families …